Novartis India (NSE:NOVARTIND) Quality Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:NOVARTIND Novartis India Ltd NSE:NOVARTIND
62 GF Score
Price ₹1,634.90
GF Value ₹1,010.65
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Novartis India Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Novartis India Quality Rank Related Terms

NSE:NOVARTIND
62GF Score
Novartis India Ltd NSE:NOVARTIND
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Novartis India (NSE:NOVARTIND) Overvalued in 2026?

Based on GuruFocus' analysis, Novartis India stock appears to be overvalued. The current stock price of ₹1,634.90 is trading 61.8% above its estimated GF Value™ of ₹1,010.65. GuruFocus considers Novartis India to be Significantly Overvalued.

Key valuation signals for NSE:NOVARTIND:

  • Quality Rank:
  • GF Value™: ₹1,010.65 vs. price of ₹1,634.90 (61.8% above fair value)
  • GF Score™: 62/100 with 7 warning signs

No single metric tells the full story. See the NSE:NOVARTIND stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Novartis India Business Description

Other Exchanges 500672:India
Address Inspire BKC, Part of 601 & 701, Bandra Kurla Complex, Bandra (East), Mumbai, MH, IND, 400 051
Novartis India Ltd is an Indian-based pharmaceutical company. The company is engaged in the trading of Drugs and Pharmaceuticals. It derives revenue from operations in India. The company operates in a single business segment, namely Pharmaceutical Business. Its Pharmaceutical business focuses on Bone and Pain, Transplantation Immunology, and Neurosciences.
62GF Score

Get the complete analysis for NSE:NOVARTIND

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,634.90
Price
₹1,010.65
GF Value